What this means
This review proposes ideas for research on energy-based skin devices in people taking GLP-1 drugs. It does not show that any device is safe or works for this group.
Plain-English summary written by an AI model from the abstract. The original is below.
- Who it was tested in
- A narrative review of published studies; no new patients were treated
- Kind of research
- A summary of earlier studies
The science
- Original title
- Energy-Based Devices for GLP-1 Receptor Agonist-Associated Facial Aging: A Tissue-Specific Safety Framework.
- Authors
- Cho CH, Koo S, Yoo K
- Journal
- Clinical, cosmetic and investigational dermatology
- Published
- Oct 18, 2026
- Study type
- Review
- PMID
- 42893183 ↗
Abstract
Glucagon-like peptide-1 receptor agonist (GLP-1RA)-associated rapid weight loss may be accompanied by facial changes resembling accelerated aging, colloquially termed "Ozempic face". In this review, this proposed phenotype is termed GLP-1RA-associated facial accelerated aging (GLP-1RA-FAA) and is characterized primarily by facial volume loss and skin laxity, with possible but incompletely characterized alterations in dermal-adipose support, adipose-derived stem-cell biology, fibroblast-extracellular-matrix homeostasis, and facial muscle. Demand for energy-based device (EBD) treatment in this population is increasing; however, whether conventional EBD parameters are effective or safe in medication-associated facial volume depletion is unknown. A narrative review was informed by structured searches of PubMed/MEDLINE, Embase, Web of Science, and the Cochrane Library from January 2000 through August 31, 2026. Evidence was selected for clinical directness and relevance to radiofrequency, high-intensity focused ultrasound, broadband light, microwave, extracorporeal shock wave therapy, diode laser, and synchronized radiofrequency with high-intensity facial electrical stimulation. Available modalities differ in their intended tissue depth and in the potential relevance of three conceptual targets: preservation of adipose tissue, dermal fibroblast-extracellular-matrix remodeling, and facial muscle-SMAS support. Preclinical body-contouring studies suggest that sustained subcutaneous heating in the approximate 43-45°C range can be associated with adipocyte injury or apoptosis; however, no facial thermal dose threshold has been established, particularly in GLP-1RA-treated patients. No individual EBD modality has demonstrated simultaneous restoration of adipose, dermal, and muscle-related targets in prospective GLP-1RA-specific studies. Conservative control of treatment depth, careful avoidance of unnecessary deep energy deposition in volume-depleted regions, investigation of low-intensity dermal remodeling strategies, and evaluation of muscle-targeting approaches are proposed as research considerations. These concepts are hypothesis generating and do not constitute clinical recommendations or standards of care. Prospective controlled studies in well-characterized GLP-1RA-treated populations are required before device-specific protocols can be adopted.
Cho CH, Koo S, Yoo K Energy-Based Devices for GLP-1 Receptor Agonist-Associated Facial Aging: A Tissue-Specific Safety Framework. Clinical, cosmetic and investigational dermatology. 2026. doi:10.2147/CCID.S628537. PMID: 42893183. https://pubmed.ncbi.nlm.nih.gov/42893183/
Related research
Lessons from dog lifespan therapeutics for their human companions.
The growing evidence that existing cardio-renal-metabolic therapies, such as GLP-1 receptor agonists and SGLT2 inhibitors, confer all-cause mortality benefits has positioned them as the first wave of potential…
Semaglutide may slow some biological aging clocks in adults with HIV
In a trial of 84 adults, semaglutide was linked to slower aging scores on several blood-based measures. This was an extra analysis not planned at the start, so it cannot prove the drug slows aging.
See all research on GLP-1 drugs →